ExploreWatchlistsPricing
  1. JP-listed companies
  2. AnGes, Inc.
  3. Financials
  4. Revenue

AnGes, Inc. (4563)

Market cap
¥22.6B
P/E ratio
-2.2x
AnGes develops gene medicines and nucleic acid treatments, while providing genetic screening tests for rare disorders through its clinical research laboratory.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Dec 31, 2025874+35.81%
Dec 31, 2024644+320.72%
Dec 31, 2023153+128.13%
Dec 31, 202267+4.54%
Dec 31, 202164+60.38%
Dec 31, 202040-87.76%
Dec 31, 2019327-46.44%
Dec 31, 2018610+67.05%
Dec 31, 2017365-28.99%
Dec 31, 2016514+19.55%
Dec 31, 2015430-52.73%
Dec 31, 2014910+85.20%
Dec 31, 2013491+10.53%
Dec 31, 2012445+82.63%
Dec 31, 2011243

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat